UNSPSC 51473501: Hexetidine

This classification denotes an anti-infective agent with the molecular formula C21H45N3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 852A84Y8LS, chemically known as 1,3-bis(2-ethylhexyl)hexahydro-5-methyl-5-pyrimidiamine but generally known as hexetidine, which bears US NIH Compound Identifier 3607. European Medicines Agency schedules Hexetidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08037MIG.

UNSPSC 51473501 Hexetidine, a Commodity code, covers antimicrobial oral rinses and throat lozenges that state and local governments procure for public health facilities, fire departments, and cooperative pharmaceutical purchasing programs. The code appears in both janitorial supply bundles for operational use across public safety infrastructure and in multi-state pharmaceutical cooperative purchasing vehicles serving health systems and government-operated clinics. Issuing bodies soliciting under this code include county commissioners' offices managing fire rescue operations and state procurement agencies administering multi-state cooperative purchasing alliances for pharmaceutical distribution.

Hillsborough County (Florida) and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) represent the recent activity. Hillsborough County Board of County Commissioners issued ITB2600319 on July 7, 2026, seeking consumable janitorial and operational supplies including hexetidine-based products for the Hillsborough County Fire Rescue Department's 47 stations, with bids due July 24, 2026 and an estimated contract value of $765,679.84 for one year. MMCAP, administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 on January 20, 2026, establishing multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities in Minnesota and Oregon, with proposals due March 26, 2026 and awards effective July 1, 2026. Vendors must comply with cGMP and Drug Supply Chain Security Act requirements, maintain relationships with authorized wholesalers, and accept a 3 percent administrative fee on contract purchases.